Last $8.60 USD
Change Today +0.17 / 2.02%
Volume 58.5K
HSGX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 8:10 PM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Peter S. Greenleaf

Former Chief Executive Officer and Director, Histogenics Corporation
AgeTotal Calculated CompensationThis person is connected to 107 board members in 2 different organizations across 7 different industries.

See Board Relationships
44--
As of Fiscal Year 2013

Background*

Mr. Peter S. Greenleaf has been the Chief Executive Officer of Sucampo Pharmaceuticals, Inc. since March 03, 2014. Mr. Greenleaf served as Chief Executive Officer of Histogenics Corporation from June 10, 2013 to February 28, 2014 and served as its President. Mr. Greenleaf served as President of MedImmune, LLC (also known as MedImmune, Inc.). Mr. Greenleaf also served as President of MedImmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group, ...

Read Full Background

Corporate Headquarters*

830 Winter Street
Waltham, Massachusetts 02451

United States

Phone: 781-547-7900
Fax: 781-547-4452

Board Members Memberships*

Former Director
Director
Former Chief Executive Officer and Director
Former Director
2010-N/A
Former Director
2014-Present
Chief Executive Officer, Director, Member of Commercialization Committee and Member of Science & Technology Committee

Education*

MBA
Saint Joseph's University
BA
Western Connecticut State University

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

There is no Total Compensation data available.
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HSGX:US $8.60 USD +0.17

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Mark R. Baker J.D.Chief Executive Officer, Director and Member of Science & Strategy Committee
Progenics Pharmaceuticals, Inc.
$535.6K
Craig A. Wheeler Chief Executive Officer, President and Executive Director
Momenta Pharmaceuticals Inc.
$621.0K
A. J. Kazimi MBAFounder, Chairman, Chief Executive Officer and President
Cumberland Pharmaceuticals, Inc.
$620.0K
Douglas L. Drysdale Chairman, Chief Executive Officer and President
Pernix Therapeutics Holdings, Inc.
--
Jeffrey M. Yordon Founder, Chairman and Chief Executive Officer
Sagent Pharmaceuticals, Inc.
$615.2K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HISTOGENICS CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.